Effects of Genetic and Pharmacologic Inhibition of COX-2 on Colitis-associated Carcinogenesis in Mice|RISS 상세보기

다국어 초록 (Multilingual Abstract)

COX-2 has been inappropriately overexpressed in various human malignancies, and is considered as one of the representative targets for the chemoprevention of inflammation-associated cancer. In order to assess the role of COX-2 in colitis-induced carcinogenesis, the selective COX-2 inhibitor celecoxib and COX-2 null mice were exploited in an azoxymethane (AOM)-initiated and dextran sulfate sodium (DSS)-promoted murine colon carcinogenesis model. The administration of 2% DSS in drinking water for 1 week after a single intraperitoneal injection of AOM produced colorectal adenomas in 83% of mice, whereas only 27% of mice given AOM alone developed tumors. Oral administration of celecoxib significantly lowered the incidence as well as the multiplicity of colon tumors. The expression of COX-2 and inducible nitric oxide synthase (iNOS) was upregulated in the colon tissues of mice treated with AOM and DSS, and this was inhibited by celecoxib administration. Likewise, celecoxib treatment abrogated the DNA binding of NF-κB, a key transcription factor responsible for regulating expression of aforementioned pro-inflammatory enzymes, which was associated with suppression of IκBα degradation. In the COX-2 null ( COX-2 –/–) mice, there was about 30% reduction in the incidence of colon tumors, and the tumor multiplicity was also markedly reduced (7.7 ± 2.5 vs. 2.43 ± 1.4, P < 0.01). As both pharmacologic inhibition and genetic ablation of COX-2 gene could not completely suppress colon tumor formation following treatment with AOM and DSS, it is speculated that other pro-inflammatory mediators, including COX-1 and iNOS, should be additionally targeted to prevent inflammation-associated colon carcinogenesis.
Key Words Chemoprevention, Celecoxib, Colitis, Colon cancer, COX-2

번역하기

참고문헌 (Reference)

1 Ishikawa TO, "Tumor formation in a mouse model of colitis-associated colon cancer does not require COX-1or COX-2 expression" 31 : 729-736, 2010

2 Giardiello FM, "Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis" 328 : 1313-1316, 1993

3 Matuk R, "The spectrum of gastrointestinal toxicity and effect on disease activity of selective cyclooxygenase-2 inhibitors in patients with inflammatory bowel disease" 10 : 352-356, 2004

4 Wang D, "The role of COX-2 in intestinal inflammation and colorectal cancer" 29 : 781-788, 2010

5 Hamilton MJ, "The multifaceted mast cell in inflammatory bowel disease" 20 : 2364-2378, 2014

6 Steinbach G, "The effect of celecoxib, a cyclooxygenase-2inhibitor, in familial adenomatous polyposis" 342 : 1946-1952, 2000

7 Wright JM, "The double-edged sword of COX-2 selective NSAIDs" 167 : 1131-1137, 2002

8 Levy R, "Sulindac in familial adenomatous polyposis" 347 : 615-, 2002

9 Zucker S, "Role of matrix metalloproteinases(MMPs)in colorectal cancer" 23 : 101-117, 2004

10 Morham SG, "Prostaglandin synthase 2 gene disruption causes severe renal pathology in the mouse" 83 : 473-482, 1995